Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany

• Main Authors: Bjoern Jensen (Author), Nadine Luebke (Author), Torsten Feldt (Author), Verena Keitel (Author), Timo Brandenburger (Author), Detlef Kindgen-Milles (Author), Matthias Lutterbeck (Author), Noemi F Freise (Author), David Schoeler (Author), Rainer Haas (Author), Alexander Dilthey (Author), Ortwin Adams (Author), Andreas Walker (Author), Joerg Timm (Author), Tom Luedde (Author)
• Format: Book
• Published: Elsevier, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally,...